- Home
- DSGN vs PHT Comparison
DSGN vs PHT Comparison
Compare DSGN & PHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- PHT
- Stock Information
- Founded
- DSGN 2017
- PHT 2002
- Country
- DSGN United States
- PHT United States
- Employees
- DSGN N/A
- PHT N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- PHT Investment Managers
- Sector
- DSGN Health Care
- PHT Finance
- Exchange
- DSGN Nasdaq
- PHT Nasdaq
- Market Cap
- DSGN 264.4M
- PHT 225.6M
- IPO Year
- DSGN 2021
- PHT N/A
- Fundamental
- Price
- DSGN $5.88
- PHT $7.88
- Analyst Decision
- DSGN Hold
- PHT
- Analyst Count
- DSGN 3
- PHT 0
- Target Price
- DSGN $7.00
- PHT N/A
- AVG Volume (30 Days)
- DSGN 370.1K
- PHT 85.5K
- Earning Date
- DSGN 08-05-2024
- PHT 01-01-0001
- Dividend Yield
- DSGN N/A
- PHT 8.76%
- EPS Growth
- DSGN N/A
- PHT N/A
- EPS
- DSGN N/A
- PHT 0.98
- Revenue
- DSGN N/A
- PHT N/A
- Revenue This Year
- DSGN N/A
- PHT N/A
- Revenue Next Year
- DSGN N/A
- PHT N/A
- P/E Ratio
- DSGN N/A
- PHT $7.71
- Revenue Growth
- DSGN N/A
- PHT N/A
- 52 Week Low
- DSGN $1.96
- PHT $6.41
- 52 Week High
- DSGN $6.91
- PHT $7.60
- Technical
- Relative Strength Index (RSI)
- DSGN 64.21
- PHT 61.59
- Support Level
- DSGN $4.50
- PHT $7.81
- Resistance Level
- DSGN $6.91
- PHT $7.89
- Average True Range (ATR)
- DSGN 0.50
- PHT 0.05
- MACD
- DSGN 0.06
- PHT -0.00
- Stochastic Oscillator
- DSGN 50.62
- PHT 75.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.